



38th Annual JP Morgan Healthcare Conference

Anthony Fernando, President & CEO
January 16, 2020

FORWARD LOOKING STATEMENTS


This presentation includes statements relating to TransEnterix's regulatory and commercialization plans for the Senhance Surgical System and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the commercialization of the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, our current cash reach, the effect on our business on existing and new regulatory requirements and other economic and competitive factors and whether we will be able to execute upon our corporate objectives. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 27, 2019 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OUR STRATEGIC INTENT

At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today's value-based healthcare environment.

TRANSENERIX: TRXC

COMMERCIAL STAGE COMPANY USHERING IN A NEW ERA OF
MINIMALLY INVASIVE SURGERY



- **Senhance Surgical Robotic System** – the first and only **Digital Laparoscopy** platform
- Significant addressable market opportunity
- FDA Cleared, CE Marked and Japan PMDA approved
- Ramping up clinical adoption
- Well positioned to bring Augmented Intelligence (AI) and Machine Vision to surgery

COMPANY SNAPSHOT


FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL ROBOTICS
IN NEARLY 20 YEARS

NYSE American: Listed
2014 (TRXC)

170+
Employees

100+
Surgeon Users

2,500+
Cases Completed




GLOBAL TRENDS IN ROBOTIC SURGERY


SURGICAL ROBOTICS IS A LARGE AND FAST GROWING MARKET
AND LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY

Surgical robotics market (\$bn)

- In the U.S., robotic surgery is <10% of surgery today, after nearly 20 years
- Continued expansion into additional procedures and new global markets
- Broadening solution sets enabled by new market entrants



Laparoscopic greenfield opportunity



Historical growth drivers:

- Convert open surgeries to robotics
- Offset significant cost with length of stay benefit vs. open surgery

Future growth drivers:

- Convert laparoscopic surgeries to robotics
- Improve laparoscopy: designed for greater precision, efficiencies, safety, ergonomics
- Provide meaningful robotic benefits to laparoscopic surgery without significant per procedure cost increase

VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION

THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER
THE CONSTRAINTS OF VALUE-BASED HEALTHCARE



OR
Inefficiencies



Surgical
Variability



Workforce
Challenges



Laparoscopy is the most widely performed surgical technique and carries limitations that compound these factors and can impact clinical outcomes

REALITIES THAT WILL DRIVE GROWTH IN SURGICAL ROBOTICS



AN OPPORTUNITY AND NEED TO ADD TO THE WAYS SURGICAL ROBOTICS CREATES VALUE

THE MARKET

- Increasingly majority of growth in robotic assisted procedures will come from laparoscopy



RIGHT SIZE ROBOTICS

- Hospitals are seeking ways to shift higher volume procedures to lower cost settings
- Reimbursement rates globally will not increase to support adding cost for robotic assistance

THE FUTURE

- Digital information and decision support tools will be the primary driver of the added value through computer assistance

WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY

	On the Market	In Development	Product Strategy → Implications
Digital Laparoscopy	<p>Senhance</p>  <p>US✓ EU✓ JP✓</p>		<p>Lap motion → Familiarity for Laparoscopic surgeons</p> <p>Fully reusable instruments → Low cost per procedure</p> <p>Standard 5mm and 3mm Instruments → Advances MIS benefit</p> <p>Haptic feedback → Restores significant sensory input to surgery</p> <p>Eye tacking camera control → Novel and satisfying surgical vision control</p> <p>Open vision system → Leverage best in class visualization technologies</p> <p>Individual boom arms → Full patient access</p> <p>Articulating instruments → Enabling where needed</p>
Robotic Assisted Surgery	<p>Da Vinci</p>  <p>US✓ EU✓ JP✓</p>	<p>Medtronic VERB CMR</p>	<p>Open motion → More enabling for non-laparoscopists</p> <p>Limited use/Single use instruments → High cost per procedure</p> <p>Wristed instruments → Enabling but higher cost per procedure</p> <p>8mm and 5mm instruments → Not improving invasiveness over laparoscopy</p>

SENHANCE SYSTEM ADDRESSES KEY CHALLENGES FACING HOSPITALS AND LAPAROSCOPIC SURGEONS

BUILDING THE BRIDGE FROM LAPAROSCOPY TO ROBOTICS


First robotic system to offer the security of haptic feedback

First robotic system to offer simultaneous surgeon-controlled visualization

86 different types of procedure/technique surgeries performed

New standard in minimally invasive surgery with **3mm** instruments


Developed broad instrument portfolio with **70** instruments in the catalog



STRONG, BROAD-BASED CLINICAL PERFORMANCE

SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE
ACROSS THE THREE MAJOR GEOGRAPHIES


GLOBAL CLINICAL CASE VOLUME TREND



Active Sites	6	15	24 +60% vs PY
Total Cases	394	552	1612 +192% vs PY

Strong clinical case performance in 2019


2019 CASE MIX




Adoption across multiple specialty areas,
demonstrating broader applicability and adoption

DIGITAL LAPAROSCOPY PLATFORM – MORE THAN THE ROBOT


OUR VISION FOR DIGITAL LAPAROSCOPY GOES BEYOND THE ROBOT




**ROBOTIC
MANIPULATION**




**OPEN PLATFORM
ARCHITECTURE**




**INTELLIGENT
SCENE COGNITION**



**AUGMENTED
INTELLIGENCE**



CONNECTIVITY




**OPERATING ROOM
WORKFLOW**


AUGMENTED INTELLIGENCE AND MACHINE VISION IN SURGERY

RECENT FDA SUBMISSION LAYING THE FOUNDATION FOR DIGITIZING SURGERY AND LEVERAGE COMPUTER TOOLS


SENHANCE INTELLIGENT SURGICAL UNIT



DEFECT IDENTIFICATION AND SIZING



3D POINT TO POINT MEASUREMENT



CRITICAL STRUCTURE IDENTIFICATION



FUTURE FEATURE ADDITIONS

MILESTONES

SYSTEMATIC ACCOMPLISHMENT OF KEY GOALS PAVING THE WAY FOR CONTINUED SUCCESS

2017

- Senhance FDA 510(k) clearance
- 3mm instrument CE mark and launch
- Stryker, Novadaq, Richard-Wolf vision system compatibility

2018

- Hernia & Gall Bladder indication expansion FDA 510(k)
- 3mm instrument 510(k) clearance and US launch
- Ultrasonic Advanced Energy instrument CE mark and EU launch
- Articulating Instrument CE mark
- STORZ vision system compatibility
- Taiwan regulatory clearance for Senhance
- Acquired MST assets and set up Israel R&D center

2019

- Ultrasonic Advanced Energy instrument 510(K) clearance and US launch
- Next Gen Eye-Tracking system launch
- 4K monitor and enhanced vision
- Upgraded system software with enhanced performance
- Olympus 3D and 4K vision system compatibility
- Stryker 4K vision system compatibility
- Surgical training simulator launch
- **Japan Regulatory Approval of Senhance System**
- **Japan Reimbursement for 98 Laparoscopic procedures**
- Pediatric Indication expansion CE submission

2020 – SENHANCE AND DIGITAL LAPAROSCOPY RECOGNIZED AS KEY COMPONENTS FOR ROBOTIC GROWTH

TECHNOLOGY THAT HAS THE ABILITY TO “RIGHT SIZE ROBOTICS”

MARKET DEVELOPMENT

- Expand the number of sites using the Senhance System in the United States, Europe, and Japan
- Double the number of clinical cases
- Increase the number of speakers & advocates cascading our key messages

CLINICAL EVIDENCE

- Publication of evidence supporting Senhance value propositions
 - Cost Effectiveness
 - Ergonomics
 - Clinical Outcomes
 - O.R. Efficiency

PORTFOLIO EXPANSION

- Scene cognition and Augmented Intelligence technology launched in the US
- Full EU launch of 5mm Articulating instruments
- Indication expansion
 - General Surgery in US
 - Bariatric in US
 - Pediatric in EU

By End 2020 – Critical mass of advocacy, awareness, and credibility developed as a foundation to drive future growth



SenhanceSurgery

WHEN YOU **DIGITIZE THE
INTERFACE** BETWEEN THE
SURGEON AND THE PATIENT,
SURGERY BECOMES **SAFER
AND MORE PREDICTABLE**



